Document is current
Any future updates will be listed below
-
Authors
Ozmen, Furkan
Ozmen, Tugba Y.
Ors, Aysegul
Janghorban, Mahnaz
Rames, Matthew J.
Li, Xi
Doe, Aaron Reid
Behbod, Fariba
Mills, Gordon B.
Mohammed, Hisham
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation (BCRF-24-110, BCRF-24-110, BCRF-24-110)
National Cancer Institute (NCI U01 CA 281902, NCI U01 CA 281902, NCI U01 CA 281902)
- License Information
-
More Information
Article History
Received: 19 April 2025
Accepted: 26 July 2025
First Online: 26 August 2025
Competing interests
: Gordon B. Mills serves or has served as a scientific advisory board member or consultant for Amphista, Astex, AstraZeneca, BlueDot, Ellipses Pharmaceuticals, ImmunoMET, Leapfrog Bio, Bruker/Nanostring, Neophore, Nerviano, Nuvectis, Pangea, PDX Pharmaceuticals, Qureator, Rybodyne, Signalchem Lifesciences, Turbine, and Zentalis Pharmaceuticals; holds stock, stock options, or other financial interests in Bluedot, Catena Pharmaceuticals, ImmunoMet, Nuvectis, RyboDyne, SignalChem Lifesciences, and Turbine; is an inventor on licensed technology, including an HRD assay licensed to Myriad Genetics and DSP patents licensed to Nanostring; and has received sponsored research support from AstraZeneca, Zentalis, and Nanostring. The other authors declare no financial or non-financial competing interests.
